Early antipsychotic response to aripiprazole in adolescents with schizophrenia: Predictive value for clinical outcomes

Journal of the American Academy of Child and Adolescent Psychiatry

Volumn 52, Issue 7, 2013, Pages

  Correll, Christoph U ^a   Zhao, Joan ^b   Carson, William ^b   Marcus, Ron ^c   McQuade, Robert ^b   Forbes, Robert A ^b   Mankoski, Raymond ^d  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b Otsuka Pharmaceutical Development and Commercialization   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d Department of Clinical Research   (United States)

Author keywords

adolescent schizophrenia; antipsychotics; early response; remission; response prediction

Indexed keywords

ARIPIPRAZOLE; PLACEBO;

ADOLESCENT; ARTICLE; CLINICAL DECISION MAKING; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ONSET AGE; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; POSITIVE AND NEGATIVE SYNDROME SCALE; PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REMISSION; RISK ASSESSMENT; SCHIZOPHRENIA; SELF REPORT; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 84879504121     PISSN: 08908567     EISSN: 15275418     Source Type: Journal    
DOI: 10.1016/j.jaac.2013.04.018     Document Type: Article

References (53)

1. C.M. Young, and R.L. Findling Pharmacologic treatment of adolescent and child schizophrenia Expert Rev Neurotherapeut 4 2004 53 60
2. A.K. Mattai, J.L. Hill, and R.K. Lenroot Treatment of early-onset schizophrenia Curr Opin Psychiatry 23 2010 304 310
3. L. Sikich Efficacy of atypical antipsychotics in early-onset schizophrenia and other psychotic disorders J Clin Psychiatry 69 suppl 4 2008 21 25
4. American Academy of Child and Adolescent Psychiatry. Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry. In press.
5. M. Bodnar, A. Malla, R. Joober, and M. Lepage Cognitive markers of short-term clinical outcome in first-episode psychosis Br J Psychiatry 193 2008 297 304
6. K. Salimi, L.F. Jarskog, and J.A. Lieberman Antipsychotic drugs for first-episode schizophrenia: a comparative review CNS Drugs 23 2009 837 855
7. O. Agid, S. Kapur, T. Arenovich, and R.B. Zipursky Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected Arch Gen Psychiatry 60 2003 1228 1235
8. B.J. Kinon, L. Chen, and H. Ascher-Svanum Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia Schizophr Res 102 2008 230 240
9. C.U. Correll, A.K. Malhotra, S. Kaushik, M. McMeniman, and J.M. Kane Early prediction of antipsychotic response in schizophrenia Am J Psychiatry 160 2003 2063 2065
10. S. Leucht, R. Busch, J. Hamann, W. Kissling, and J. Kane Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended Biol Psychiatry 57 2005 1543 1549
11. S. Leucht, R. Busch, W. Kissling, and J.M. Kane Early prediction of antipsychotic nonresponse among patients with schizophrenia J Clin Psychiatry 68 2007 352 360
12. B.J. Kinon, L. Chen, and H. Ascher-Svanum Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia Neuropsychopharmacology 35 2010 581 590
13. Y.C. Chang, H.Y. Lane, K.H. Yang, and C.L. Huang Optimizing early prediction for antipsychotic response in schizophrenia J Clin Psychopharmacol 26 2006 554 559
14. H. Ascher-Svanum, A.W. Nyhuis, D.E. Faries, B.J. Kinon, R.W. Baker, and A. Shekhar Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia Schizophr Bull 34 2008 1163 1171
15. C. Lin, L. Chou, C. Lin, C. Hsu, Y. Chen, and H.Y. Lane Early prediction of clinical response in schizophrenia patients receiving the atypical antipsychotic zotepine J Clin Psychiatry 68 2007 1522 1527
16. C.U. Correll, C.J. Kratochvil, and J.S. March Developments in pediatric psychopharmacology: focus on stimulants, antidepressants, and antipsychotics J Clin Psychiatry 72 2011 655 670
17. D. Fraguas, C.U. Correll, and J. Merchán-Naranjo Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons Eur Neuropsychopharmacol 21 2011 621 645
18. S. Kumra, J.V. Oberstar, and L. Sikich Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia Schizophr Bull 34 2008 60 71
19. L. Sikich, R.M. Hamer, R.A. Bashford, B.B. Sheitman, and J.A. Lieberman A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial Neuropsychopharmacology 29 2004 133 145
20. L. Sikich, J.A. Frazier, and J. McClellan Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) study Am J Psychiatry 165 2008 1420 1431
21. C.U. Correll Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes J Am Acad Child Adolesc Psychiatry 47 2008 9 20
22. C.U. Correll Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents J Clin Psychiatry 69 suppl 4 2008 26 36
23. C.U. Correll, and J.M. Kane One-year incidence rates of tardive dyskinesia in children and adolescents treated with second-generation antipsychotics: a systematic review J Child Adolesc Psychopharmacol 17 2007 647 656
24. C.U. Correll, P. Manu, V. Olshanskiy, B. Napolitano, J.M. Kane, and A.K. Malhotra Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents JAMA 302 2009 1765 1773
25. M. De Hert, M. Dobbelaere, E.M. Sheridan, D. Cohen, and C.U. Correll Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice Eur Psychiatry 26 2011 144 158
26. R.L. Findling, J.L. Johnson, and J. McClellan Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study J Am Acad Child Adolesc Psychiatry 49 2010 583 594 quiz 632
27. C.U. Correll, T. Lencz, and A.K. Malhotra Antipsychotic drugs and obesity Trends Mol Med 17 2011 97 107
28. S.M. Stahl, and D.K. Shayegan The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice J Clin Psychiatry 64 suppl 19 2003 6 12
29. A. Farah Atypicality of atypical antipsychotics Prim Care Companion J Clin Psychiatry 7 2005 268 274
30. C.U. Correll From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics Eur Psychiatry 25 suppl 2 2010 S12 S21
31. J.M. Kane, and C.U. Correll Past and present progress in the pharmacologic treatment of schizophrenia J Clin Psychiatry 71 2010 1115 1124
32. K.D. Burris, T.F. Molski, and C. Xu Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors J Pharmacol Exp Ther 302 2002 381 389
33. Y. Tadori, R.A. Forbes, R.D. McQuade, and T. Kikuchi Characterization of aripiprazole partial agonist activity at human dopamine D receptors Eur J Pharmacol 597 2008 27 33
34. S. Jordan, V. Koprivica, R. Dunn, K. Tottori, T. Kikuchi, and C.A. Altar In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function Eur J Pharmacol 483 2004 45 53
35. S. Jordan, V. Koprivica, R. Chen, K. Tottori, T. Kikuchi, and C.A. Altar The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT(1A) receptor Eur J Pharmacol 441 2002 137 140
36. B.M. Kuehn FDA panel OKs 3 antipsychotic drugs for pediatric use, cautions against overuse JAMA 302 2009 833 834
37. R.L. Findling, A. Robb, and M. Nyilas A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia Am J Psychiatry 165 2008 1432 1441
38. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 4th ed, text rev 2000 American Psychiatric Publishing Washington, DC
39. J. Kaufman, B. Birmaher, and D. Brent Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data J Am Acad Child Adolesc Psychiatry 36 1997 980 988
40. S.R. Kay, L.A. Opler, and J.P. Lindenmayer Reliability and validity of the positive and negative syndrome scale for schizophrenics Psychiatry Res 23 1988 99 110
41. W. Guy Clinical Global Impressions (CGI). ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education, and Welfare Publication (ADM) 76-338 1976 National Institute of Mental Health Rockville, MD 218-222
42. D. Shaffer, M.S. Gould, and J. Brasic A Children's Global Assessment Scale (CGAS) Arch Gen Psychiatry 40 1983 1228 1231
43. J. Endicott, J. Nee, R. Yang, and C. Wohlberg Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q): reliability and validity J Am Acad Child Adolesc Psychiatry 45 2006 401 407
44. G.M. Simpson, and J.W. Angus A rating scale for extrapyramidal side effects Acta Psychiatr Scand Suppl 212 1970 11 19
45. T.R. Barnes A rating scale for drug-induced akathisia Br J Psychiatry 154 1989 672 676
46. W. Guy Abnormal Involuntary Movement Scale (AIMS) US Department of Health Education and Welfare. ECDEU Assessment Manual for Psychopharmacology 1976 National Institute of Mental Health Rockville, MD 534-537
47. S. Leucht, J.M. Kane, E. Etschel, W. Kissling, J. Hamann, and R.R. Engel Linking the PANSS, BPRS, and CGI: clinical implications Neuropsychopharmacology 31 2006 2318 2325
48. N.C. Andreasen, W.T. Carpenter Jr., J.M. Kane, R.A. Lasser, S.R. Marder, and D.R. Weinberger Remission in schizophrenia: proposed criteria and rationale for consensus Am J Psychiatry 162 2005 441 449
49. B.G. Schimmelmann, S.J. Schmidt, M. Carbon, and C.U. Correll A Rational, Evidence Informed Approach to Psychopharmacology for Adolescents with Early Onset, First Episode Psychoses Curr Opin Psychiatry 26 2013 219 230
50. J.A. Gallego, D.G. Robinson, and S.M. Sevy Time to treatment response in first-episode schizophrenia: should acute treatment trials last several months? J Clin Psychiatry 72 2011 1691 1696
51. E.M. Derks, W.W. Fleischhacker, H. Boter, J. Peuskens, and R.S. Kahn Antipsychotic drug treatment in first-episode psychosis: should patients be switched to a different antipsychotic drug after 2, 4, or 6 weeks of nonresponse? J Clin Psychopharmacol 30 2010 176 180
52. R. Emsley, J. Rabinowitz, and R. Medori Time course for antipsychotic treatment response in first-episode schizophrenia Am J Psychiatry 163 2006 743 745
53. R. Emsley, P.P. Oosthuizen, M. Kidd, L. Koen, D.J. Niehaus, and H.J. Turner Remission in first-episode psychosis: predictor variables and symptom improvement patterns J Clin Psychiatry 67 2006 1707 1712